By API User
Key Facts: · Superior Tumour Inhibition – INOVIQ’s CAR-NK-EV therapeutic candidate achieved 61.5% tumour reduction over 28 days, outperforming unmodified NK-EVs · 100% Survival – All mice treated with CAR-NK-EVs survived the study period, compared to 66.7% for controls · Excellent Safety Profile – CAR-NK-EV treatment was well tolerated, with no observable adverse effects · … Continued
By API User
At the tail end of a record-breaking flu year, the Royal Australian College of GPs (RACGP) has reminded patients and families to stay safe over the holiday period. Health reporting shows influenza cases have continued to climb in the summer, while flu deaths have been higher than those associated with COVID-19 for the past four … Continued
By API User
Key Facts: Tucatinib, a breast cancer drug, will be listed on PBS, saving patients over $4,500 per month The drug is specifically for HER2-positive metastatic breast cancer patients, particularly those with brain metastases Interviews: Larissa King – woman living with breast cancer that has spread to the brain Vicki Durston. BCNA Director Policy, Advocacy and … Continued
By API User
The Royal Australian College of General Practitioners (RACGP) WA Faculty has honoured outstanding contributions to general practice at its annual awards ceremony, celebrating leaders, educators, registrars, and practices across the state. The evening provided the opportunity to celebrate the College’s highest honour, the Rose-Hunt Award, awarded during GP25, which was presented to WA GP, Adjunct … Continued
By API User
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need SAN CARLOS, Calif.–BUSINESS WIRE– BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the … Continued
By API User
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was … Continued
By API User
La Trobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more … Continued
By API User
Hepatitis Australia has today welcomed the Australian Government’s investment in viral hepatitis prevention, testing and treatment measures and community-led initiatives announced in the Mid-Year Economic and Fiscal Outlook (MYEFO). The national Hepatitis peak said that the additional funding comes at a critical moment in Australia’s push to eliminate hepatitis B and hepatitis C by 2030 … Continued
By API User
Dementia Australia is reminding Australians that dementia support and information is available 24 hours a day, seven days a week throughout the holiday period, which can be a challenging time for people living with dementia, their families and carers. The National Dementia Helpline 1800 100 500, will remain open for information and support across the … Continued
By API User
MEDIA RELEASE Thursday, 18 December 2025 ANZGOG welcomes three new Board Directors, expanding expertise and strengthening governance to advance gynaecological cancer research The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is pleased to announce the appointment of three new Board Directors: Beth Slatyer, Catherine Whitby GAICD and Grace Chu GAICD. They will join ANZGOG’s existing Board, comprising 12 esteemed leaders with deep … Continued
